세계의 세균 백신 시장 - 산업규모, 점유율, 동향, 기회, 예측, 백신 유형별, 환자 연령층별, 유통 채널별, 투여 경로별, 지역별 부문, 경쟁(2020-2030년)
Bacterial Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Patient Age Group, By Distribution Channel, By Route of Administration, By Region & Competition, 2020-2030F
세균 백신 세계 시장은 2024년에 71억 달러로 평가되었으며, 2030년까지 CAGR은 7.20%를 나타낼 전망입니다.
세균 면역 또는 세균 백신으로도 알려진 세균 백신은 신체의 면역계를 자극하여 특정 세균 병원체를 인식하고 싸우도록 설계된 예방 의학의 한 유형입니다. 이 백신은 세균 성분과 불활성화된 세균 세포를 사용하여 만들어지며 다양한 세균 감염에 대한 면역성을 제공합니다. 세균 백신은 심각한 질병과 합병증을 일으키고 심지어 죽음에 이르기까지 다양한 세균 감염을 예방하는 데 매우 중요합니다. 백신에 의해 예방되는 일반적인 세균 질환에는 파상풍, 디프테리아, 백일해, 폐렴, 수막염 등이 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
71억 달러 |
| 시장 규모 : 2030년 |
106억 9,000만 달러 |
| CAGR : 2025-2030년 |
7.20% |
| 급성장 부문 |
주사용 백신 |
| 최대 시장 |
북미 |
세균 백신에 의한 백신 접종의 보급은 접종자를 보호할 뿐만 아니라 집단 면역에도 기여합니다. 이것은 특정 건강 상태에 있는 사람이나 면역력이 저하된 사람 등 의료상의 이유로 백신을 접종할 수 없는 사람을 간접적으로 지키게 됩니다. 세균 백신은 특히 저소득 및 중산층 국가에서 세계 건강 활동에 중요한 역할을 하고 있습니다. 예방 접종 프로그램은 세균성 질환의 부담을 줄이고 아이의 생존율을 높이고 전체 공중 보건을 향상시킵니다. 예를 들어, 2025년 미국 질병 예방관리센터(CDC)에 따르면 집단 감염으로 75,968명의 사례가 보고되었으며, 4,235명이 사망했으며, 이는 전염병 확산의 중요한 영향을 강조합니다.
시장 성장 촉진요인
신종 감염
주요 시장 과제
백신 주저
주요 시장 동향
파이프라인 개발
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 세균 백신 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 백신 유형별(백일해 백신, 파상풍 백신, 디프테리아 백신, 폐렴구균 백신, 수막염균 백신, 장티푸스 백신, 결핵 백신, 콜레라 백신, 세균성 이질 백신, 기타)
- 환자 연령 그룹별(소아 백신(유아, 어린이), 청소년 백신, 성인 백신, 고령자 백신)
- 유통 채널별(정부 기관 및 프로그램, 병원 및 진료소, 소매 약국, 온라인 약국, 기타)
- 투여 경로별(주사 백신, 경구 백신, 비강 백신)
- 지역별
- 기업별(2024)
- 시장 맵
제6장 아시아태평양의 세균 백신 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 세균 백신 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 북미의 세균 백신 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제9장 남미의 세균 백신 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 세균 백신 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 세균 백신 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Pfizer Inc.
- GSK plc
- Novartis AG
- Mylan NV
- Sanofi SA
- Boehringer Ingelheim International GmbH.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Bharat Biotech International Ltd
- Serum Institute of India Pvt. Ltd
제17장 전략적 제안
제18장 기업 소개와 면책사항
SHW
Global Bacterial Vaccines Market was valued at USD 7.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2030. Bacterial vaccines, also known as bacterial immunizations or bacterial vaccines, are a type of preventive medicine designed to stimulate the body's immune system to recognize and fight against specific bacterial pathogens. These vaccines are created using components of bacteria or inactivated bacterial cells to provide immunity against various bacterial infections. Bacterial vaccines are crucial for preventing a wide range of bacterial infections that can cause serious illnesses, complications, and even death. Common bacterial diseases prevented by vaccines include tetanus, diphtheria, pertussis, pneumonia, and meningitis.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 7.10 Billion |
| Market Size 2030 | USD 10.69 Billion |
| CAGR 2025-2030 | 7.20% |
| Fastest Growing Segment | Injectable Vaccines |
| Largest Market | North America |
Widespread vaccination with bacterial vaccines not only protects vaccinated individuals but also contributes to herd immunity. This indirectly protects those who cannot receive vaccines due to medical reasons, such as individuals with certain health conditions or weakened immune systems. Bacterial vaccines play a critical role in global health efforts, especially in low- and middle-income countries. Vaccination programs reduce the burden of bacterial diseases, improve child survival rates, and enhance overall public health. For instance, according to the Centers for Disease Control and Prevention (CDC) in 2025, outbreaks resulted in 75,968 reported human cases and 4,235 deaths, highlighting the significant impact of infectious disease spread.
Key Market Drivers
Emerging Infectious Diseases
Emerging Infectious Diseases (EIDs) are diseases that have recently appeared in a population or have existed but are rapidly increasing in incidence or geographic range. These diseases often pose a significant threat to public health because they are novel, poorly understood, and may lack effective treatments. Bacterial EIDs can include diseases caused by antibiotic-resistant strains or previously unrecognized pathogens. Bacterial vaccines are crucial tools for the prevention and control of emerging bacterial infections. They provide a proactive approach to combat new threats by preparing populations with immunity against specific bacterial pathogens. In the event of an outbreak of an emerging bacterial infection, rapid vaccination campaigns can be implemented to contain the spread of the disease. This is particularly important in preventing large-scale epidemics or pandemics. For instance, according to WHO 2024, better vaccine use could cut antibiotic use by 2.5 billion doses annually, preventing deaths from antimicrobial resistance, reducing treatment costs, and curbing the spread of resistant infections.
Key Market Challenges
Vaccine Hesitancy
Vaccine hesitancy refers to the reluctance or refusal of individuals or communities to accept vaccines, despite the availability of vaccination services. This hesitancy can manifest for various reasons, including safety concerns, misinformation, and distrust of vaccines and healthcare systems. Vaccine hesitancy can lead to lower vaccination rates, which means that fewer individuals are protected against bacterial infections. This can result in pockets of susceptible individuals within a community, increasing the risk of disease outbreaks. Lower vaccine coverage due to hesitancy reduces the level of herd immunity within a population. This not only puts unvaccinated individuals at risk but also makes it easier for bacterial diseases to spread within the community. Vaccine hesitancy can impede public health efforts to control bacterial infections. Diseases that were once well-controlled can experience resurgence when vaccine coverage declines. A rise in vaccine-preventable diseases due to hesitancy can strain healthcare systems, leading to increased healthcare costs associated with treating these diseases and their complications. Governments and healthcare organizations must allocate resources to combat vaccine hesitancy through public health campaigns, educational initiatives, and outreach efforts. These resources could be used elsewhere if hesitancy was not a factor. Reduced demand for bacterial vaccines may affect funding for research and development of new vaccines and improvements to existing ones. Pharmaceutical companies may be less motivated to invest in vaccine development if there is lower demand. The spread of misinformation and vaccine-related myths on social media platforms can contribute to vaccine hesitancy. False information can erode public trust in vaccines and healthcare providers. Safety concerns, whether founded in evidence or not, can lead to hesitancy. High-profile vaccine safety scares can have lasting effects on public perception.
Key Market Trends
Pipeline Developments
Pharmaceutical companies and research institutions are actively working on expanding their portfolio of bacterial vaccines. This includes developing vaccines for a wide range of bacterial pathogens responsible for various infectious diseases. The emergence of new bacterial pathogens or the reemergence of existing ones often prompts the development of vaccines to address these threats. Recent examples include vaccine development efforts in response to antibiotic-resistant strains of bacteria. Advances in vaccine technology, including the use of novel adjuvants, recombinant DNA technology, and conjugate vaccine platforms, are driving innovation in bacterial vaccine development. These technologies can improve vaccine efficacy and safety. Research is focused on developing highly targeted vaccines that are effective against specific bacterial strains or serotypes. Precision in vaccine design is important for combating antibiotic-resistant bacteria. Some pipeline developments involve multivalent vaccines that target multiple bacterial strains or serotypes in a single vaccine formulation. This can simplify vaccination schedules and improve coverage. International organizations and governments are supporting vaccine research and development for bacterial diseases that disproportionately affect low- and middle-income countries. These initiatives are aimed at reducing global health disparities. Recent pandemics, such as COVID-19, have highlighted the importance of vaccine development for emerging infectious diseases, including those caused by bacterial pathogens. Preparedness efforts include research into rapid vaccine development platforms.
Key Market Players
- Pfizer Inc.
- GSK plc
- Novartis AG
- Mylan N.V.
- Sanofi SA
- Boehringer Ingelheim International GmbH.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Bharat Biotech International Ltd
- Serum Institute of India Pvt. Ltd
Report Scope:
In this report, the Global Bacterial Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Bacterial Vaccines Market, By Vaccine Type:
- Pertussis (Whooping Cough) Vaccines
- Tetanus Vaccines
- Diphtheria Vaccines
- Pneumococcal Vaccines
- Meningococcal Vaccines
- Typhoid Vaccines
- Tuberculosis (TB) Vaccines
- Cholera Vaccines
- Shigellosis Vaccines
- Others
Bacterial Vaccines Market, By Patient Age Group:
- Pediatric Vaccines (Infants, Children)
- Adolescent Vaccines
- Adult Vaccines
- Geriatric Vaccines
Bacterial Vaccines Market, By Distribution Channel:
- Government Agencies and Programs
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
- Others
Bacterial Vaccines Market, By Route of Administration:
- Injectable Vaccines
- Oral Vaccines
- Nasal Vaccines
Bacterial Vaccines Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Vaccines Market.
Available Customizations:
Global Bacterial Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bacterial Vaccines Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others)
- 5.2.2. By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines)
- 5.2.3. By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others)
- 5.2.4. By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Bacterial Vaccines Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Vaccine Type
- 6.2.2. By Patient Age Group
- 6.2.3. By Distribution Channel
- 6.2.4. By Route of Administration
- 6.2.5. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Bacterial Vaccines Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Vaccine Type
- 6.3.1.2.2. By Patient Age Group
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.2.4. By Route of Administration
- 6.3.2. India Bacterial Vaccines Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Vaccine Type
- 6.3.2.2.2. By Patient Age Group
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.2.4. By Route of Administration
- 6.3.3. Australia Bacterial Vaccines Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Vaccine Type
- 6.3.3.2.2. By Patient Age Group
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.2.4. By Route of Administration
- 6.3.4. Japan Bacterial Vaccines Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Vaccine Type
- 6.3.4.2.2. By Patient Age Group
- 6.3.4.2.3. By Distribution Channel
- 6.3.4.2.4. By Route of Administration
- 6.3.5. South Korea Bacterial Vaccines Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Vaccine Type
- 6.3.5.2.2. By Patient Age Group
- 6.3.5.2.3. By Distribution Channel
- 6.3.5.2.4. By Route of Administration
7. Europe Bacterial Vaccines Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Vaccine Type
- 7.2.2. By Patient Age Group
- 7.2.3. By Distribution Channel
- 7.2.4. By Route of Administration
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Bacterial Vaccines Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Vaccine Type
- 7.3.1.2.2. By Patient Age Group
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.2.4. By Route of Administration
- 7.3.2. Germany Bacterial Vaccines Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Vaccine Type
- 7.3.2.2.2. By Patient Age Group
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.2.4. By Route of Administration
- 7.3.3. Spain Bacterial Vaccines Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Vaccine Type
- 7.3.3.2.2. By Patient Age Group
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.2.4. By Route of Administration
- 7.3.4. Italy Bacterial Vaccines Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Vaccine Type
- 7.3.4.2.2. By Patient Age Group
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.2.4. By Route of Administration
- 7.3.5. United Kingdom Bacterial Vaccines Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Vaccine Type
- 7.3.5.2.2. By Patient Age Group
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.2.4. By Route of Administration
8. North America Bacterial Vaccines Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Vaccine Type
- 8.2.2. By Patient Age Group
- 8.2.3. By Distribution Channel
- 8.2.4. By Route of Administration
- 8.2.5. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Bacterial Vaccines Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Vaccine Type
- 8.3.1.2.2. By Patient Age Group
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.2.4. By Route of Administration
- 8.3.2. Mexico Bacterial Vaccines Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Vaccine Type
- 8.3.2.2.2. By Patient Age Group
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.2.4. By Route of Administration
- 8.3.3. Canada Bacterial Vaccines Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Vaccine Type
- 8.3.3.2.2. By Patient Age Group
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.2.4. By Route of Administration
9. South America Bacterial Vaccines Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Vaccine Type
- 9.2.2. By Patient Age Group
- 9.2.3. By Distribution Channel
- 9.2.4. By Route of Administration
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Bacterial Vaccines Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Vaccine Type
- 9.3.1.2.2. By Patient Age Group
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.2.4. By Route of Administration
- 9.3.2. Argentina Bacterial Vaccines Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Vaccine Type
- 9.3.2.2.2. By Patient Age Group
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.2.4. By Route of Administration
- 9.3.3. Colombia Bacterial Vaccines Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Vaccine Type
- 9.3.3.2.2. By Patient Age Group
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.2.4. By Route of Administration
10. Middle East and Africa Bacterial Vaccines Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Vaccine Type
- 10.2.2. By Patient Age Group
- 10.2.3. By Distribution Channel
- 10.2.4. By Route of Administration
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Bacterial Vaccines Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Vaccine Type
- 10.3.1.2.2. By Patient Age Group
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.2.4. By Route of Administration
- 10.3.2. Saudi Arabia Bacterial Vaccines Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Vaccine Type
- 10.3.2.2.2. By Patient Age Group
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.2.4. By Route of Administration
- 10.3.3. UAE Bacterial Vaccines Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Vaccine Type
- 10.3.3.2.2. By Patient Age Group
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.2.4. By Route of Administration
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Bacterial Vaccines Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Pfizer Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. GSK plc
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
- 16.3. Novartis AG
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
- 16.4. Mylan N.V.
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
- 16.5. Sanofi SA
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
- 16.6. Boehringer Ingelheim International GmbH.
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
- 16.7. Merck & Co., Inc.
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
- 16.8. F. Hoffmann-La Roche Ltd.
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
- 16.9. Bristol-Myers Squibb Company
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
- 16.10.Bharat Biotech International Ltd
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis
- 16.11. Serum Institute of India Pvt. Ltd
- 16.11.1. Business Overview
- 16.11.2. Company Snapshot
- 16.11.3. Products & Services
- 16.11.4. Financials (In case of listed companies)
- 16.11.5. Recent Developments
- 16.11.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer
